ArticleBMC infectious diseases2017
Molecular epidemiology of bla
Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Multicenter Analytical Performance Evaluation of the BD Phoenix NMIC-461 Panel for Carbapenemase Classification and Antimicrobial Susceptibility Testing ofAntibiotics (Basel, Switzerland) · 2026Article
- Molecular analysis of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Recombinant Expression of a New Antimicrobial Peptide Composed of hBD-3 and hBD-4 in Escherichia coli and Investigation of Its Activity Against Multidrug-Resistant Bacteria.Probiotics and antimicrobial proteins · 2025Article
- Genotyping of Acinetobacter baumannii clinical isolates from Polish hospitals uncovers novel sequence types.Scientific reports · 2025Article
- Unveiling meropenem resistance and co-resistance patterns in Klebsiella pneumoniae and Acinetobacter baumannii: a global genome analysis using ML/DL and association mining.BMC microbiology · 2025Article
- Gastrointestinal carriage of carbapenemase-producing enterobacterales among inpatient and outpatient children in Kenya.Scientific reports · 2024Article
- Molecular epidemiology of Acinetobacter baumannii during COVID-19 at a hospital in northern China.Annals of clinical microbiology and antimicrobials · 2024Article
- Seasonal meropenem resistance in Acinetobacter baumannii and influence of temperature-driven adaptation.BMC microbiology · 2024Article
- Molecular and virulence characteristics of carbapenem-resistant Acinetobacter baumannii isolates: a prospective cohort study.Scientific reports · 2023Article
- Molecular and clinical epidemiology of carbapenem resistantThe Lancet regional health. Western Pacific · 2023Article
- A review on the mechanistic details of OXA enzymes of ESKAPE pathogens.Pathogens and global health · 2023Review
- Local characteristics of molecular epidemiolgy of Acinetobacter baumannii in Jilin province (northeast China).BMC microbiology · 2023Article
- Prevalent DominantInfection and drug resistance · 2023Article
- Phenotypic and genomic comparison of dominant and nondominant sequence-type ofFrontiers in cellular and infection microbiology · 2023Article
- The Molecular Detection of Class B and Class D Carbapenemases in Clinical Strains ofAntibiotics (Basel, Switzerland) · 2022Article
- Resistance traits and molecular characterization of multidrug-resistant Acinetobacter baumannii isolates from an intensive care unit of a tertiary hospital in Guangdong, southern China.International microbiology : the official journal of the Spanish Society for Microbiology · 2022Article
- Effects of amikacin, polymyxin-B, and sulbactam combination on the pharmacodynamic indices of mutant selection against multi-drug resistantFrontiers in microbiology · 2022Article
- Molecular Characterization of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Antibacterial effect of carbon nanotube containing chemical compounds on drug-resistant isolates ofIranian journal of microbiology · 2021Article
- Whole-Genome Sequencing Elucidates the Epidemiology of Multidrug-ResistantFrontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCarbapenem-resistant Acinetobacter baumannii poses a significant threat to hospitalized patients, as few therapeutic options remain. Thus, we investigated the molecular epidemiology and mechanism of resistance of carbapenem-resistant A.baumannii isolates in Beijing, China.
methodsCarbapenem-resistant A.baumannii isolates (n = 101) obtained between June 2009 and November 2014 were used. Multilocus sequence typing (MLST) and PCR assays for class C and D β-lactamase were performed on all isolates. S1 nuclease pulsed-field gel electrophoresis (PFGE) and Southern blot hybridization were performed to identify the resistance gene location.
resultsAll 101 A.baumannii isolates were highly resistant to frequently used antimicrobials, and were considered multidrug resistant. A total of 12 sequence types (STs) were identified, including 10 reported STs and 2 novel STs. Eighty-seven isolates were classified to clonal complex 92 (CC92), among which ST191 and ST195 were the most common STs. The bla
conclusionbla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.